申请人:Imperial Chemical Industries Limited
公开号:US04251528A1
公开(公告)日:1981-02-17
This invention relates to enzyme inhibitory, novel phthalazin-4-ylacetic acid derivatives of the general formula I: ##STR1## and pharmaceutically acceptable salts as appropriate, to pharmaceutical compositions thereof, and to analogy processes for their manufacture. The compounds of formula I are inhibitors of the enzyme aldose reductase in vivo and as such may be useful in the reduction or prevention of the development of the peripheral effects such as macular oedema, cataract, retinopathy or impaired neural conduction. A preferred compound is 2-(2-fluoro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4-ylacetic acid.
这项发明涉及一种酶抑制剂,通式I的新型邻苯二氮杂环戊酸衍生物:##STR1## 以及在适当情况下的药学上可接受的盐,其制药组合物,以及制造它们的类似方法。通式I的化合物是体内醣醇还原酶的抑制剂,因此可能对减少或预防外周效应的发展具有用处,例如黄斑水肿、白内障、视网膜病变或神经传导受损。一种优选化合物是2-(2-氟-4-溴苯基)-1,2-二氢-1-氧代邻苯二氮杂环戊酸。